This study concerns the effects of several pre-transplant features on outcome for patients with beta thalassemia major who underwent bone marrow transplantation (BMT). Seventy patients with beta thalassemia major underwent bone marrow transplantation during the period 1991-1997 in Shariati Hospital in Tehran, Iran. The survival and rejection curves levelled off at 8 and 18 months after transplantation at 82.6% and 11.4%, respectively. Pre-transplant clinical features (age, serum ferritin, portal fibrosis, hepatomegaly and quality of chelation therapy) were examined for their effects on survival and recurrence of thalassemia in this group of patients who were less than 16 years old. Increasing age, presence of portal fibrosis and increasing serum ferritin were significantly associated with reduced probability of survival (P = 0.0047, P = 0.016 and P = 0.024, respectively). Hepatomegaly and inadequate pretransplant chelation therapy which were documented as poor prognostic factors in previous studies, were not evaluable in this study. We also showed the benefits of transplanting more than 5.5 ؋ 10 8 /kg cells in this group of patients with no increase in complications. Keywords: marrow transplantation; thalassemia; prognostic factors Homozygous ␤-thalassemia is a congenital hemolytic anemia due to a genetic defect in globulin chain synthesis. Thalassemia is probably the most common single gene disorder causing a major public health problem in the world. In the absence of specific gene therapy, allogeneic bone marrow transplantation is the only rational therapeutic modality for eradication of beta thalassemia major.
Homozygous ␤-thalassemia is a congenital hemolytic anemia due to a genetic defect in globulin chain synthesis. Thalassemia is probably the most common single gene disorder causing a major public health problem in the world. 1 In the absence of specific gene therapy, allogeneic bone marrow transplantation is the only rational therapeutic modality for eradication of beta thalassemia major. 2 The effects of pre-transplant prognostic factors on BMT outcome were reviewed for the first time by Lucarelli et al in a large series of patients who had been transplanted in Pesaro, Italy. [3] [4] [5] They concluded that for patients under 16 years of age, transplantation of bone marrow offers a high probability of complication-free survival, particularly in the absence of hepatomegaly, portal fibrosis and history of poor chelation therapy. 
Methods
Between March 1991 and September 1997, 70 patients between the ages of 2.5 and 16 years underwent BMT in Shariati Hospital in Tehran, Iran. In 67 cases, donor and recipient were genotypically HLA identical siblings and in three cases they were phenotypically identical. Thirty-eight patients were male and 32 female. In the presence of major ABO incompatibility, red cells were removed from donor marrow by sedimentation with hydroxy ethyl starch. The mean number of cells transplanted was 5.5 × 10 8 /kg (s.d. = 1.9). For all patients regardless of age, busulfan was administered orally at a dose of 3.5 mg per kg per day in three divided doses for 4 days (total dose:14 mg per kg). This treatment was followed by 50 mg of cyclophosphamide per kg intravenously on each of 4 successive days. All patients received cyclosporin A and methotrexate (10 mg/m 2 on days 1, 3, 6 and 11) to prevent acute graftversus-host disease. Cyclosporin A was administered intravenously at a dose of 5 mg per kg the day before transplantation and changed to the oral route 5 days later at a dose of 12.5 mg per kg. Reverse isolation was used, along with a diet low in bacteria. Improving hemoglobin levels and comparison of cytogenetic studies before and after BMT were used as criteria for engraftment. Liver biopsies were performed before admission to the BMT ward and examined for presence of portal fibrosis by an expert pathologist.
Statistical methods
The Kaplan-Meier method was used to estimate the probabilities of survival and rejection. The log rank test was used to estimate the significance of differences. The Cox regression model was also used to support the results obtained by the Kaplan-Meier analysis. Factors such as age and serum ferritin were considered as continuous variables. Comparing means was carried out by Mann-Whitney U test.
Results
Twelve patients died and 57 are alive. One of our patients, who was splenectomized before BMT, died due to pneumococcal meningitis, 26 months after BMT. As she had not received prophylactic antibiotics, this death was not counted as a BMT-related death. The survival and rejection curves levelled off at 8 months and 18 months after transplant at 82.6% and 11.4%, respectively ( Figure 1 ). The latest death was on day 245 and was due to rejection and subsequent CNS hemorrhage. The longest surviving patient is alive and disease-free nearly 6 years after transplantation. The factors presented in Table 1 were examined for their influence on survival and rejection. When we examined the effects of the two age groups (Ͻ9 and у9 years) on survival, there was a significantly better outcome for patients under 9 years age (P = 0.0047). In a continuous model, increasing age again had significant effects on survival (P = 0.02) and indeed this model revealed that there is a 1.2 times increment in hazard for every year of increase in age. Although ferritin levels were shown to influence survival (P = 0.0016) when divided into two groups (Ͻ1500 and у1500 g/l), this effect was less obvious when the grouping was omitted. Presence of portal fibrosis was also associated with a worse outcome (P = 0.02). We could not obtain a valid assessment regarding the effects of hepatomegaly and quality of chelation therapy on survival with the above-mentioned statistical methods, because only two patients died without hepatomegaly and with history of good chelation therapy. Age (Ͻ9 and у9 years) was the only pre-transplant factor which affected rejection rate (P = 0.037). Other factors including serum ferritin, portal fibrosis, splenomegaly, hepatomegaly and inadequate chelation therapy did not have any influence on rejection rate (P = 0.41, P = 0.5, P = 0.6 respectively) in spite of some previous reports. [3] [4] [5] [6] According to the classification described by Lucarelli et al, [3] [4] [5] 7 25 (35.7%) of our patients were in class I, 32 (45.7%) in class II and 13 (18.6%) in class III. The mortality was 2 (8.3%) in class I, 5 (15.6%) in class II and 5 (38.5%) in class III with a median followup of 2.5 years. Increasing mortality in terms of this classification approached significance in our study (P = 0.06 by Fisher exact test).
Death was due to acute GVHD in five patients, sepsis and ARDS in two, venocclusive disease in one, rejection in two, interstitial pneumonitis in one and unknown etiology in one of our patients. Comparison of median count recovery time (WBC Ͼ1000/ml, neutrophil Ͼ500/ml and platelet Ͼ50 000/ml) in the two groups of patients who had received more or less than 5.5 × 10 8 /kg cells at BMT revealed a faster platelet recovery (P = 0.01) in the first group, while this did not hold true with regard to WBC recovery (P = 0.1) ( Table 2) .
There was less requirement for red cell and platelet transfusions in the post-transplant period (P = 0.01 and P = 0.001, respectively) when more than 5.5 × 10 8 /kg cells had been transplanted. Although the advantages of more Table 2 Comparison between two transplanted cell number groups Neu = neutrophils; PC = transfused packed cell units; PLT = transfused platelet units; HS = hospital stay; AGVHD = acute graft-versus-host disease; NS = not significant. cells at transplant have been well established, 8 it is worth stating that increasing the number of cells transplanted to more than 5.5 × 10 8 /kg does not increase mortality or incidence of grade III and IV acute GVHD in our patients (P = 0.3) but does increase the overall incidence of acute GVHD (P = 0.04). There was no correlation between an increased number of transplanted cells and incidence of chronic GVHD (P = 0.85). The incidence of acute GVHD was 71% in this series. The incidence of grade I acute GVHD was 30.4% (21 patients), grade II, 26.1% (18 patients), grade III, 7.2% (five patients) and grade IV, 7.2% (five patients).
Discussion
Although we have one of the largest series of patients transplanted for thalassemia (probably the second after the Pesaro team), the number of patients was insufficient to permit valid conclusions to be made in many fields. For example, we could not assess the effects of hepatomegaly and chelation therapy on BMT outcome. Both of these factors have been recognized as important in terms of outcome after BMT for thalassemia. Prognostic factors proposed by Lucarelli et al for BMT for beta thalassemia major, reflect the severity of organ insult from iron overload. It seems that iron overload and its consequent organ failure limit compensatory mechanisms for overcoming various BMTrelated stresses.
The majority of our patients had a poor history of chelation therapy and hepatomegaly (45 out of 70). Indeed age in this group of patients represent the duration of exposure to iron overload. In developing countries, therapy for beta thalassemia major is sometimes inadequate and usually offered late. This may be due to poor socio-economic circumstances of some patients, inadequate knowledge by parents about the disease, inadequate training of physicians in distant cities in management of thalassemia and difficulties in preparing and using the Desferal pump. Developing countries are the home of the majority of thalassemic patients world-wide. 1, 9 As the majority of our cases had a poor history of chelation therapy and hepatomegaly, it is not possible to ascertain outcome solely based on these factors. We conclude, however, that we can add age (Ͻ9 and у9 years) to the classic classification and thereby overcome this problem.
Although it is established knowledge, 8 we also showed the benefits of transplanting more than 5.5 × 10 8 /kg cells on cell recovery time and in reducing the need for post-BMT blood product transfusions. As this cell dose did not increase the incidence of grade III or IV acute GVHD or result in more chronic GVHD, we recommend it for bone marrow transplantation in thalassemia.
